,2 The use of intravitreal vascular endothelial growth factor (VEGF)-neutralizing agents has revolutionized the treatment of the neovascular component of AMD referred to as choroidal neovascularization (CNV). This evidence concerns the gene VEGFA and choroidal neovascularization.